We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Hidradenitis Suppurativa

News List

Exploring Vitamin Treatments for Hidradenitis Suppurativa: Focus on Isotretinoin David Orchard-Webb
January 30, 2024
Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and tunnels developing in areas where skin rubs together.
MC2 Therapeutics Acquires Option to Phase 2 Oral Drug Candidate for Hidradenitis Suppurativa and Other Indications B3C newswire
November 06, 2023
MC2 Therapeutics announced today that it has acquired option rights from Regranion, LLC to exclusively license Regranion’s RGRN-305 for the treatment of all human diseases, incl, oral treatment of HS globally, excluding the greater China region.
Risk for Long-Term Opioid Use Up in Hidradenitis Suppurativa drugs
September 12, 2019
Patients with hidradenitis suppurativa (HS) have an increased risk for long-term opioid use, according to a study published online in JAMA Dermatology.